nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Propranolol—Penbutolol—coronary artery disease	0.23	1	CrCrCtD
Duloxetine—HTR2A—coronary artery disease	0.182	1	CbGaD
Duloxetine—CYP1A2—Gemfibrozil—coronary artery disease	0.0336	0.184	CbGbCtD
Duloxetine—CYP1A2—Clopidogrel—coronary artery disease	0.0292	0.16	CbGbCtD
Duloxetine—CYP2D6—Niacin—coronary artery disease	0.0182	0.0998	CbGbCtD
Duloxetine—CYP2D6—Timolol—coronary artery disease	0.0169	0.0928	CbGbCtD
Duloxetine—CYP2D6—Captopril—coronary artery disease	0.0149	0.0817	CbGbCtD
Duloxetine—CYP2D6—Simvastatin—coronary artery disease	0.0144	0.0789	CbGbCtD
Duloxetine—CYP1A2—Losartan—coronary artery disease	0.0142	0.0781	CbGbCtD
Duloxetine—CYP2D6—Lovastatin—coronary artery disease	0.0141	0.0772	CbGbCtD
Duloxetine—CYP2D6—Pravastatin—coronary artery disease	0.0141	0.0772	CbGbCtD
Duloxetine—CYP2D6—Atorvastatin—coronary artery disease	0.0128	0.0703	CbGbCtD
Duloxetine—SLC6A2—sympathetic nervous system—coronary artery disease	0.00383	0.152	CbGeAlD
Duloxetine—HTR2A—arteriole—coronary artery disease	0.00361	0.143	CbGeAlD
Duloxetine—Cinacalcet—CASR—coronary artery disease	0.00264	0.699	CrCbGaD
Duloxetine—SLC6A2—autonomic nervous system—coronary artery disease	0.00257	0.102	CbGeAlD
Duloxetine—HTR2A—pulmonary artery—coronary artery disease	0.00237	0.0937	CbGeAlD
Duloxetine—HTR2A—sympathetic nervous system—coronary artery disease	0.0023	0.0911	CbGeAlD
Duloxetine—HTR2A—vagus nerve—coronary artery disease	0.00223	0.0882	CbGeAlD
Duloxetine—HTR2A—vein—coronary artery disease	0.00215	0.0852	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—coronary artery disease	0.00155	0.0612	CbGeAlD
Duloxetine—NPY1R—blood—coronary artery disease	0.00118	0.0468	CbGeAlD
Duloxetine—HTR2A—artery—coronary artery disease	0.000877	0.0347	CbGeAlD
Duloxetine—HTR2A—endothelium—coronary artery disease	0.000741	0.0293	CbGeAlD
Duloxetine—SLC6A4—blood—coronary artery disease	0.000455	0.018	CbGeAlD
Duloxetine—HTR2A—heart—coronary artery disease	0.000323	0.0128	CbGeAlD
Duloxetine—CYP1A2—blood—coronary artery disease	0.000308	0.0122	CbGeAlD
Duloxetine—HTR2A—cardiovascular system—coronary artery disease	0.000305	0.0121	CbGeAlD
Duloxetine—HTR2A—blood—coronary artery disease	0.000241	0.00954	CbGeAlD
Duloxetine—CYP2D6—blood—coronary artery disease	0.00022	0.00869	CbGeAlD
Duloxetine—Fluoxetine—CYP2C19—coronary artery disease	0.000199	0.0528	CrCbGaD
Duloxetine—Propranolol—ADRB1—coronary artery disease	0.000168	0.0445	CrCbGaD
Duloxetine—Fluoxetine—HTR2A—coronary artery disease	0.000161	0.0428	CrCbGaD
Duloxetine—Propranolol—ADRB2—coronary artery disease	0.000141	0.0374	CrCbGaD
Duloxetine—Atomoxetine—CYP2C19—coronary artery disease	0.000128	0.0339	CrCbGaD
Duloxetine—Propranolol—CYP2C19—coronary artery disease	0.000121	0.0322	CrCbGaD
Duloxetine—Fluoxetine—ALB—coronary artery disease	0.00011	0.0293	CrCbGaD
Duloxetine—Atomoxetine—HTR2A—coronary artery disease	0.000104	0.0275	CrCbGaD
Duloxetine—Dermatitis—Ezetimibe—coronary artery disease	4.63e-05	0.000183	CcSEcCtD
Duloxetine—Confusional state—Ramipril—coronary artery disease	4.63e-05	0.000182	CcSEcCtD
Duloxetine—Discomfort—Timolol—coronary artery disease	4.63e-05	0.000182	CcSEcCtD
Duloxetine—Asthenia—Niacin—coronary artery disease	4.62e-05	0.000182	CcSEcCtD
Duloxetine—Fatigue—Losartan—coronary artery disease	4.62e-05	0.000182	CcSEcCtD
Duloxetine—Headache—Ezetimibe—coronary artery disease	4.61e-05	0.000182	CcSEcCtD
Duloxetine—Malaise—Lisinopril—coronary artery disease	4.6e-05	0.000181	CcSEcCtD
Duloxetine—Anaphylactic shock—Ramipril—coronary artery disease	4.59e-05	0.000181	CcSEcCtD
Duloxetine—Oedema—Ramipril—coronary artery disease	4.59e-05	0.000181	CcSEcCtD
Duloxetine—Vertigo—Lisinopril—coronary artery disease	4.59e-05	0.000181	CcSEcCtD
Duloxetine—Dry mouth—Timolol—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Pain—Losartan—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Constipation—Losartan—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Syncope—Lisinopril—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Vomiting—Eplerenone—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Feeling abnormal—Furosemide—coronary artery disease	4.58e-05	0.00018	CcSEcCtD
Duloxetine—Leukopenia—Lisinopril—coronary artery disease	4.57e-05	0.00018	CcSEcCtD
Duloxetine—Nausea—Fenofibrate—coronary artery disease	4.56e-05	0.00018	CcSEcCtD
Duloxetine—Pruritus—Niacin—coronary artery disease	4.56e-05	0.00018	CcSEcCtD
Duloxetine—Asthenia—Pravastatin—coronary artery disease	4.55e-05	0.000179	CcSEcCtD
Duloxetine—Gastrointestinal pain—Furosemide—coronary artery disease	4.54e-05	0.000179	CcSEcCtD
Duloxetine—Rash—Eplerenone—coronary artery disease	4.54e-05	0.000179	CcSEcCtD
Duloxetine—Urticaria—Perindopril—coronary artery disease	4.54e-05	0.000179	CcSEcCtD
Duloxetine—Hypersensitivity—Trandolapril—coronary artery disease	4.54e-05	0.000179	CcSEcCtD
Duloxetine—Dermatitis—Eplerenone—coronary artery disease	4.54e-05	0.000179	CcSEcCtD
Duloxetine—Diarrhoea—Valsartan—coronary artery disease	4.53e-05	0.000179	CcSEcCtD
Duloxetine—Confusional state—Timolol—coronary artery disease	4.53e-05	0.000178	CcSEcCtD
Duloxetine—Shock—Ramipril—coronary artery disease	4.52e-05	0.000178	CcSEcCtD
Duloxetine—Hypersensitivity—Enalapril—coronary artery disease	4.52e-05	0.000178	CcSEcCtD
Duloxetine—Abdominal pain—Perindopril—coronary artery disease	4.52e-05	0.000178	CcSEcCtD
Duloxetine—Body temperature increased—Perindopril—coronary artery disease	4.52e-05	0.000178	CcSEcCtD
Duloxetine—Palpitations—Lisinopril—coronary artery disease	4.51e-05	0.000178	CcSEcCtD
Duloxetine—Diarrhoea—Olmesartan—coronary artery disease	4.51e-05	0.000178	CcSEcCtD
Duloxetine—Headache—Eplerenone—coronary artery disease	4.51e-05	0.000178	CcSEcCtD
Duloxetine—Nervous system disorder—Ramipril—coronary artery disease	4.51e-05	0.000177	CcSEcCtD
Duloxetine—Thrombocytopenia—Ramipril—coronary artery disease	4.5e-05	0.000177	CcSEcCtD
Duloxetine—Oedema—Timolol—coronary artery disease	4.49e-05	0.000177	CcSEcCtD
Duloxetine—Anaphylactic shock—Timolol—coronary artery disease	4.49e-05	0.000177	CcSEcCtD
Duloxetine—Pruritus—Pravastatin—coronary artery disease	4.49e-05	0.000177	CcSEcCtD
Duloxetine—Loss of consciousness—Lisinopril—coronary artery disease	4.49e-05	0.000177	CcSEcCtD
Duloxetine—Nausea—Clopidogrel—coronary artery disease	4.48e-05	0.000177	CcSEcCtD
Duloxetine—Tachycardia—Ramipril—coronary artery disease	4.48e-05	0.000177	CcSEcCtD
Duloxetine—Skin disorder—Ramipril—coronary artery disease	4.46e-05	0.000176	CcSEcCtD
Duloxetine—Infection—Timolol—coronary artery disease	4.46e-05	0.000176	CcSEcCtD
Duloxetine—Vomiting—Simvastatin—coronary artery disease	4.46e-05	0.000176	CcSEcCtD
Duloxetine—Hypersensitivity—Telmisartan—coronary artery disease	4.46e-05	0.000176	CcSEcCtD
Duloxetine—Cough—Lisinopril—coronary artery disease	4.45e-05	0.000175	CcSEcCtD
Duloxetine—Nausea—Lovastatin—coronary artery disease	4.45e-05	0.000175	CcSEcCtD
Duloxetine—Hyperhidrosis—Ramipril—coronary artery disease	4.44e-05	0.000175	CcSEcCtD
Duloxetine—Rash—Simvastatin—coronary artery disease	4.42e-05	0.000174	CcSEcCtD
Duloxetine—Dermatitis—Simvastatin—coronary artery disease	4.42e-05	0.000174	CcSEcCtD
Duloxetine—Asthenia—Trandolapril—coronary artery disease	4.42e-05	0.000174	CcSEcCtD
Duloxetine—Shock—Timolol—coronary artery disease	4.42e-05	0.000174	CcSEcCtD
Duloxetine—Feeling abnormal—Losartan—coronary artery disease	4.42e-05	0.000174	CcSEcCtD
Duloxetine—Urticaria—Furosemide—coronary artery disease	4.41e-05	0.000174	CcSEcCtD
Duloxetine—Diarrhoea—Niacin—coronary artery disease	4.41e-05	0.000174	CcSEcCtD
Duloxetine—Nervous system disorder—Timolol—coronary artery disease	4.4e-05	0.000173	CcSEcCtD
Duloxetine—Asthenia—Enalapril—coronary artery disease	4.4e-05	0.000173	CcSEcCtD
Duloxetine—Headache—Simvastatin—coronary artery disease	4.39e-05	0.000173	CcSEcCtD
Duloxetine—Abdominal pain—Furosemide—coronary artery disease	4.39e-05	0.000173	CcSEcCtD
Duloxetine—Body temperature increased—Furosemide—coronary artery disease	4.39e-05	0.000173	CcSEcCtD
Duloxetine—Gastrointestinal pain—Losartan—coronary artery disease	4.38e-05	0.000173	CcSEcCtD
Duloxetine—Dizziness—Valsartan—coronary artery disease	4.38e-05	0.000173	CcSEcCtD
Duloxetine—Anorexia—Ramipril—coronary artery disease	4.38e-05	0.000172	CcSEcCtD
Duloxetine—Nausea—Ezetimibe—coronary artery disease	4.37e-05	0.000172	CcSEcCtD
Duloxetine—Skin disorder—Timolol—coronary artery disease	4.36e-05	0.000172	CcSEcCtD
Duloxetine—Dizziness—Olmesartan—coronary artery disease	4.36e-05	0.000172	CcSEcCtD
Duloxetine—Pruritus—Trandolapril—coronary artery disease	4.36e-05	0.000172	CcSEcCtD
Duloxetine—Myalgia—Lisinopril—coronary artery disease	4.35e-05	0.000171	CcSEcCtD
Duloxetine—Chest pain—Lisinopril—coronary artery disease	4.35e-05	0.000171	CcSEcCtD
Duloxetine—Arthralgia—Lisinopril—coronary artery disease	4.35e-05	0.000171	CcSEcCtD
Duloxetine—Hyperhidrosis—Timolol—coronary artery disease	4.34e-05	0.000171	CcSEcCtD
Duloxetine—Asthenia—Telmisartan—coronary artery disease	4.34e-05	0.000171	CcSEcCtD
Duloxetine—Pruritus—Enalapril—coronary artery disease	4.34e-05	0.000171	CcSEcCtD
Duloxetine—Diarrhoea—Pravastatin—coronary artery disease	4.34e-05	0.000171	CcSEcCtD
Duloxetine—Anxiety—Lisinopril—coronary artery disease	4.33e-05	0.000171	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	4.32e-05	0.00017	CcSEcCtD
Duloxetine—Discomfort—Lisinopril—coronary artery disease	4.29e-05	0.000169	CcSEcCtD
Duloxetine—Anorexia—Timolol—coronary artery disease	4.28e-05	0.000169	CcSEcCtD
Duloxetine—Pruritus—Telmisartan—coronary artery disease	4.28e-05	0.000169	CcSEcCtD
Duloxetine—Nausea—Eplerenone—coronary artery disease	4.28e-05	0.000168	CcSEcCtD
Duloxetine—Dizziness—Niacin—coronary artery disease	4.26e-05	0.000168	CcSEcCtD
Duloxetine—Urticaria—Losartan—coronary artery disease	4.26e-05	0.000168	CcSEcCtD
Duloxetine—Dry mouth—Lisinopril—coronary artery disease	4.25e-05	0.000167	CcSEcCtD
Duloxetine—Body temperature increased—Losartan—coronary artery disease	4.24e-05	0.000167	CcSEcCtD
Duloxetine—Abdominal pain—Losartan—coronary artery disease	4.24e-05	0.000167	CcSEcCtD
Duloxetine—Asthenia—Captopril—coronary artery disease	4.22e-05	0.000166	CcSEcCtD
Duloxetine—Diarrhoea—Trandolapril—coronary artery disease	4.21e-05	0.000166	CcSEcCtD
Duloxetine—Vomiting—Valsartan—coronary artery disease	4.21e-05	0.000166	CcSEcCtD
Duloxetine—Confusional state—Lisinopril—coronary artery disease	4.2e-05	0.000165	CcSEcCtD
Duloxetine—Diarrhoea—Enalapril—coronary artery disease	4.2e-05	0.000165	CcSEcCtD
Duloxetine—Dizziness—Pravastatin—coronary artery disease	4.19e-05	0.000165	CcSEcCtD
Duloxetine—Vomiting—Olmesartan—coronary artery disease	4.19e-05	0.000165	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Ramipril—coronary artery disease	4.19e-05	0.000165	CcSEcCtD
Duloxetine—Rash—Valsartan—coronary artery disease	4.18e-05	0.000165	CcSEcCtD
Duloxetine—Dermatitis—Valsartan—coronary artery disease	4.17e-05	0.000164	CcSEcCtD
Duloxetine—Nausea—Simvastatin—coronary artery disease	4.17e-05	0.000164	CcSEcCtD
Duloxetine—Oedema—Lisinopril—coronary artery disease	4.17e-05	0.000164	CcSEcCtD
Duloxetine—Anaphylactic shock—Lisinopril—coronary artery disease	4.17e-05	0.000164	CcSEcCtD
Duloxetine—Pruritus—Captopril—coronary artery disease	4.16e-05	0.000164	CcSEcCtD
Duloxetine—Rash—Olmesartan—coronary artery disease	4.16e-05	0.000164	CcSEcCtD
Duloxetine—Insomnia—Ramipril—coronary artery disease	4.16e-05	0.000164	CcSEcCtD
Duloxetine—Dermatitis—Olmesartan—coronary artery disease	4.15e-05	0.000164	CcSEcCtD
Duloxetine—Headache—Valsartan—coronary artery disease	4.15e-05	0.000163	CcSEcCtD
Duloxetine—Diarrhoea—Telmisartan—coronary artery disease	4.14e-05	0.000163	CcSEcCtD
Duloxetine—Infection—Lisinopril—coronary artery disease	4.14e-05	0.000163	CcSEcCtD
Duloxetine—Headache—Olmesartan—coronary artery disease	4.13e-05	0.000163	CcSEcCtD
Duloxetine—Paraesthesia—Ramipril—coronary artery disease	4.13e-05	0.000162	CcSEcCtD
Duloxetine—Shock—Lisinopril—coronary artery disease	4.1e-05	0.000161	CcSEcCtD
Duloxetine—Asthenia—Perindopril—coronary artery disease	4.1e-05	0.000161	CcSEcCtD
Duloxetine—Vomiting—Niacin—coronary artery disease	4.1e-05	0.000161	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Timolol—coronary artery disease	4.09e-05	0.000161	CcSEcCtD
Duloxetine—Hypersensitivity—Furosemide—coronary artery disease	4.09e-05	0.000161	CcSEcCtD
Duloxetine—Somnolence—Ramipril—coronary artery disease	4.08e-05	0.000161	CcSEcCtD
Duloxetine—Thrombocytopenia—Lisinopril—coronary artery disease	4.08e-05	0.000161	CcSEcCtD
Duloxetine—Dizziness—Trandolapril—coronary artery disease	4.07e-05	0.00016	CcSEcCtD
Duloxetine—Tachycardia—Lisinopril—coronary artery disease	4.07e-05	0.00016	CcSEcCtD
Duloxetine—Insomnia—Timolol—coronary artery disease	4.06e-05	0.00016	CcSEcCtD
Duloxetine—Rash—Niacin—coronary artery disease	4.06e-05	0.00016	CcSEcCtD
Duloxetine—Dermatitis—Niacin—coronary artery disease	4.06e-05	0.00016	CcSEcCtD
Duloxetine—Dizziness—Enalapril—coronary artery disease	4.06e-05	0.00016	CcSEcCtD
Duloxetine—Skin disorder—Lisinopril—coronary artery disease	4.05e-05	0.000159	CcSEcCtD
Duloxetine—Dyspepsia—Ramipril—coronary artery disease	4.04e-05	0.000159	CcSEcCtD
Duloxetine—Pruritus—Perindopril—coronary artery disease	4.04e-05	0.000159	CcSEcCtD
Duloxetine—Headache—Niacin—coronary artery disease	4.04e-05	0.000159	CcSEcCtD
Duloxetine—Paraesthesia—Timolol—coronary artery disease	4.03e-05	0.000159	CcSEcCtD
Duloxetine—Vomiting—Pravastatin—coronary artery disease	4.03e-05	0.000159	CcSEcCtD
Duloxetine—Hyperhidrosis—Lisinopril—coronary artery disease	4.03e-05	0.000159	CcSEcCtD
Duloxetine—Diarrhoea—Captopril—coronary artery disease	4.03e-05	0.000159	CcSEcCtD
Duloxetine—Dizziness—Telmisartan—coronary artery disease	4e-05	0.000158	CcSEcCtD
Duloxetine—Rash—Pravastatin—coronary artery disease	4e-05	0.000158	CcSEcCtD
Duloxetine—Dermatitis—Pravastatin—coronary artery disease	4e-05	0.000157	CcSEcCtD
Duloxetine—Decreased appetite—Ramipril—coronary artery disease	3.99e-05	0.000157	CcSEcCtD
Duloxetine—Somnolence—Timolol—coronary artery disease	3.99e-05	0.000157	CcSEcCtD
Duloxetine—Asthenia—Furosemide—coronary artery disease	3.98e-05	0.000157	CcSEcCtD
Duloxetine—Headache—Pravastatin—coronary artery disease	3.97e-05	0.000156	CcSEcCtD
Duloxetine—Anorexia—Lisinopril—coronary artery disease	3.97e-05	0.000156	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Ramipril—coronary artery disease	3.97e-05	0.000156	CcSEcCtD
Duloxetine—Fatigue—Ramipril—coronary artery disease	3.96e-05	0.000156	CcSEcCtD
Duloxetine—Dyspepsia—Timolol—coronary artery disease	3.95e-05	0.000156	CcSEcCtD
Duloxetine—Hypersensitivity—Losartan—coronary artery disease	3.95e-05	0.000155	CcSEcCtD
Duloxetine—Nausea—Valsartan—coronary artery disease	3.93e-05	0.000155	CcSEcCtD
Duloxetine—Pruritus—Furosemide—coronary artery disease	3.93e-05	0.000155	CcSEcCtD
Duloxetine—Constipation—Ramipril—coronary artery disease	3.93e-05	0.000155	CcSEcCtD
Duloxetine—Nausea—Olmesartan—coronary artery disease	3.92e-05	0.000154	CcSEcCtD
Duloxetine—Vomiting—Trandolapril—coronary artery disease	3.92e-05	0.000154	CcSEcCtD
Duloxetine—Diarrhoea—Perindopril—coronary artery disease	3.91e-05	0.000154	CcSEcCtD
Duloxetine—Decreased appetite—Timolol—coronary artery disease	3.9e-05	0.000154	CcSEcCtD
Duloxetine—Vomiting—Enalapril—coronary artery disease	3.9e-05	0.000154	CcSEcCtD
Duloxetine—Dizziness—Captopril—coronary artery disease	3.89e-05	0.000153	CcSEcCtD
Duloxetine—Rash—Trandolapril—coronary artery disease	3.88e-05	0.000153	CcSEcCtD
Duloxetine—Dermatitis—Trandolapril—coronary artery disease	3.88e-05	0.000153	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Timolol—coronary artery disease	3.88e-05	0.000153	CcSEcCtD
Duloxetine—Fatigue—Timolol—coronary artery disease	3.87e-05	0.000153	CcSEcCtD
Duloxetine—Rash—Enalapril—coronary artery disease	3.87e-05	0.000152	CcSEcCtD
Duloxetine—Dermatitis—Enalapril—coronary artery disease	3.86e-05	0.000152	CcSEcCtD
Duloxetine—Headache—Trandolapril—coronary artery disease	3.86e-05	0.000152	CcSEcCtD
Duloxetine—Vomiting—Telmisartan—coronary artery disease	3.85e-05	0.000152	CcSEcCtD
Duloxetine—Asthenia—Losartan—coronary artery disease	3.84e-05	0.000151	CcSEcCtD
Duloxetine—Headache—Enalapril—coronary artery disease	3.84e-05	0.000151	CcSEcCtD
Duloxetine—Pain—Timolol—coronary artery disease	3.84e-05	0.000151	CcSEcCtD
Duloxetine—Nausea—Niacin—coronary artery disease	3.83e-05	0.000151	CcSEcCtD
Duloxetine—Rash—Telmisartan—coronary artery disease	3.81e-05	0.00015	CcSEcCtD
Duloxetine—Dermatitis—Telmisartan—coronary artery disease	3.81e-05	0.00015	CcSEcCtD
Duloxetine—Diarrhoea—Furosemide—coronary artery disease	3.8e-05	0.00015	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Lisinopril—coronary artery disease	3.8e-05	0.00015	CcSEcCtD
Duloxetine—Pruritus—Losartan—coronary artery disease	3.79e-05	0.000149	CcSEcCtD
Duloxetine—Headache—Telmisartan—coronary artery disease	3.79e-05	0.000149	CcSEcCtD
Duloxetine—Feeling abnormal—Ramipril—coronary artery disease	3.79e-05	0.000149	CcSEcCtD
Duloxetine—Dizziness—Perindopril—coronary artery disease	3.78e-05	0.000149	CcSEcCtD
Duloxetine—Insomnia—Lisinopril—coronary artery disease	3.77e-05	0.000148	CcSEcCtD
Duloxetine—Nausea—Pravastatin—coronary artery disease	3.77e-05	0.000148	CcSEcCtD
Duloxetine—Gastrointestinal pain—Ramipril—coronary artery disease	3.76e-05	0.000148	CcSEcCtD
Duloxetine—Paraesthesia—Lisinopril—coronary artery disease	3.74e-05	0.000147	CcSEcCtD
Duloxetine—Vomiting—Captopril—coronary artery disease	3.74e-05	0.000147	CcSEcCtD
Duloxetine—Rash—Captopril—coronary artery disease	3.71e-05	0.000146	CcSEcCtD
Duloxetine—Dermatitis—Captopril—coronary artery disease	3.71e-05	0.000146	CcSEcCtD
Duloxetine—Somnolence—Lisinopril—coronary artery disease	3.7e-05	0.000146	CcSEcCtD
Duloxetine—Feeling abnormal—Timolol—coronary artery disease	3.7e-05	0.000146	CcSEcCtD
Duloxetine—Headache—Captopril—coronary artery disease	3.69e-05	0.000145	CcSEcCtD
Duloxetine—Gastrointestinal pain—Timolol—coronary artery disease	3.67e-05	0.000145	CcSEcCtD
Duloxetine—Dizziness—Furosemide—coronary artery disease	3.67e-05	0.000145	CcSEcCtD
Duloxetine—Dyspepsia—Lisinopril—coronary artery disease	3.67e-05	0.000144	CcSEcCtD
Duloxetine—Diarrhoea—Losartan—coronary artery disease	3.67e-05	0.000144	CcSEcCtD
Duloxetine—Nausea—Trandolapril—coronary artery disease	3.66e-05	0.000144	CcSEcCtD
Duloxetine—Urticaria—Ramipril—coronary artery disease	3.65e-05	0.000144	CcSEcCtD
Duloxetine—Nausea—Enalapril—coronary artery disease	3.64e-05	0.000144	CcSEcCtD
Duloxetine—Vomiting—Perindopril—coronary artery disease	3.63e-05	0.000143	CcSEcCtD
Duloxetine—Body temperature increased—Ramipril—coronary artery disease	3.63e-05	0.000143	CcSEcCtD
Duloxetine—Abdominal pain—Ramipril—coronary artery disease	3.63e-05	0.000143	CcSEcCtD
Duloxetine—Decreased appetite—Lisinopril—coronary artery disease	3.62e-05	0.000143	CcSEcCtD
Duloxetine—Rash—Perindopril—coronary artery disease	3.6e-05	0.000142	CcSEcCtD
Duloxetine—Dermatitis—Perindopril—coronary artery disease	3.6e-05	0.000142	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Lisinopril—coronary artery disease	3.6e-05	0.000142	CcSEcCtD
Duloxetine—Nausea—Telmisartan—coronary artery disease	3.59e-05	0.000142	CcSEcCtD
Duloxetine—Fatigue—Lisinopril—coronary artery disease	3.59e-05	0.000141	CcSEcCtD
Duloxetine—Headache—Perindopril—coronary artery disease	3.58e-05	0.000141	CcSEcCtD
Duloxetine—Urticaria—Timolol—coronary artery disease	3.57e-05	0.000141	CcSEcCtD
Duloxetine—Pain—Lisinopril—coronary artery disease	3.56e-05	0.00014	CcSEcCtD
Duloxetine—Constipation—Lisinopril—coronary artery disease	3.56e-05	0.00014	CcSEcCtD
Duloxetine—Body temperature increased—Timolol—coronary artery disease	3.55e-05	0.00014	CcSEcCtD
Duloxetine—Abdominal pain—Timolol—coronary artery disease	3.55e-05	0.00014	CcSEcCtD
Duloxetine—Dizziness—Losartan—coronary artery disease	3.54e-05	0.00014	CcSEcCtD
Duloxetine—Vomiting—Furosemide—coronary artery disease	3.53e-05	0.000139	CcSEcCtD
Duloxetine—Rash—Furosemide—coronary artery disease	3.5e-05	0.000138	CcSEcCtD
Duloxetine—Dermatitis—Furosemide—coronary artery disease	3.5e-05	0.000138	CcSEcCtD
Duloxetine—Nausea—Captopril—coronary artery disease	3.49e-05	0.000138	CcSEcCtD
Duloxetine—Headache—Furosemide—coronary artery disease	3.48e-05	0.000137	CcSEcCtD
Duloxetine—Feeling abnormal—Lisinopril—coronary artery disease	3.43e-05	0.000135	CcSEcCtD
Duloxetine—Gastrointestinal pain—Lisinopril—coronary artery disease	3.41e-05	0.000134	CcSEcCtD
Duloxetine—Vomiting—Losartan—coronary artery disease	3.41e-05	0.000134	CcSEcCtD
Duloxetine—Nausea—Perindopril—coronary artery disease	3.39e-05	0.000134	CcSEcCtD
Duloxetine—Hypersensitivity—Ramipril—coronary artery disease	3.38e-05	0.000133	CcSEcCtD
Duloxetine—Rash—Losartan—coronary artery disease	3.38e-05	0.000133	CcSEcCtD
Duloxetine—Dermatitis—Losartan—coronary artery disease	3.38e-05	0.000133	CcSEcCtD
Duloxetine—Headache—Losartan—coronary artery disease	3.36e-05	0.000132	CcSEcCtD
Duloxetine—Urticaria—Lisinopril—coronary artery disease	3.31e-05	0.00013	CcSEcCtD
Duloxetine—Hypersensitivity—Timolol—coronary artery disease	3.31e-05	0.00013	CcSEcCtD
Duloxetine—Nausea—Furosemide—coronary artery disease	3.3e-05	0.00013	CcSEcCtD
Duloxetine—Asthenia—Ramipril—coronary artery disease	3.3e-05	0.00013	CcSEcCtD
Duloxetine—Abdominal pain—Lisinopril—coronary artery disease	3.29e-05	0.00013	CcSEcCtD
Duloxetine—Body temperature increased—Lisinopril—coronary artery disease	3.29e-05	0.00013	CcSEcCtD
Duloxetine—Pruritus—Ramipril—coronary artery disease	3.25e-05	0.000128	CcSEcCtD
Duloxetine—Asthenia—Timolol—coronary artery disease	3.22e-05	0.000127	CcSEcCtD
Duloxetine—Nausea—Losartan—coronary artery disease	3.18e-05	0.000125	CcSEcCtD
Duloxetine—Pruritus—Timolol—coronary artery disease	3.18e-05	0.000125	CcSEcCtD
Duloxetine—Diarrhoea—Ramipril—coronary artery disease	3.14e-05	0.000124	CcSEcCtD
Duloxetine—Diarrhoea—Timolol—coronary artery disease	3.07e-05	0.000121	CcSEcCtD
Duloxetine—Hypersensitivity—Lisinopril—coronary artery disease	3.07e-05	0.000121	CcSEcCtD
Duloxetine—Dizziness—Ramipril—coronary artery disease	3.04e-05	0.00012	CcSEcCtD
Duloxetine—Asthenia—Lisinopril—coronary artery disease	2.99e-05	0.000118	CcSEcCtD
Duloxetine—Dizziness—Timolol—coronary artery disease	2.97e-05	0.000117	CcSEcCtD
Duloxetine—Pruritus—Lisinopril—coronary artery disease	2.95e-05	0.000116	CcSEcCtD
Duloxetine—Vomiting—Ramipril—coronary artery disease	2.92e-05	0.000115	CcSEcCtD
Duloxetine—Rash—Ramipril—coronary artery disease	2.9e-05	0.000114	CcSEcCtD
Duloxetine—Dermatitis—Ramipril—coronary artery disease	2.89e-05	0.000114	CcSEcCtD
Duloxetine—Headache—Ramipril—coronary artery disease	2.88e-05	0.000113	CcSEcCtD
Duloxetine—Vomiting—Timolol—coronary artery disease	2.86e-05	0.000112	CcSEcCtD
Duloxetine—Diarrhoea—Lisinopril—coronary artery disease	2.85e-05	0.000112	CcSEcCtD
Duloxetine—Rash—Timolol—coronary artery disease	2.83e-05	0.000112	CcSEcCtD
Duloxetine—Dermatitis—Timolol—coronary artery disease	2.83e-05	0.000111	CcSEcCtD
Duloxetine—Headache—Timolol—coronary artery disease	2.81e-05	0.000111	CcSEcCtD
Duloxetine—Dizziness—Lisinopril—coronary artery disease	2.76e-05	0.000109	CcSEcCtD
Duloxetine—Nausea—Ramipril—coronary artery disease	2.73e-05	0.000107	CcSEcCtD
Duloxetine—Nausea—Timolol—coronary artery disease	2.67e-05	0.000105	CcSEcCtD
Duloxetine—Vomiting—Lisinopril—coronary artery disease	2.65e-05	0.000104	CcSEcCtD
Duloxetine—Rash—Lisinopril—coronary artery disease	2.63e-05	0.000103	CcSEcCtD
Duloxetine—Dermatitis—Lisinopril—coronary artery disease	2.62e-05	0.000103	CcSEcCtD
Duloxetine—Headache—Lisinopril—coronary artery disease	2.61e-05	0.000103	CcSEcCtD
Duloxetine—Nausea—Lisinopril—coronary artery disease	2.47e-05	9.75e-05	CcSEcCtD
Duloxetine—HTR2A—Signaling Pathways—AGTR1—coronary artery disease	5.3e-06	4.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOB—coronary artery disease	5.26e-06	4.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCB3—coronary artery disease	5.23e-06	4.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—coronary artery disease	5.21e-06	4.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—coronary artery disease	5.2e-06	4.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDH2—coronary artery disease	5.2e-06	4.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—JAK2—coronary artery disease	5.19e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6R—coronary artery disease	5.18e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL10—coronary artery disease	5.18e-06	4.24e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA5—coronary artery disease	5.18e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—coronary artery disease	5.17e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLG—coronary artery disease	5.16e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KIT—coronary artery disease	5.16e-06	4.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—coronary artery disease	5.13e-06	4.2e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—P4HB—coronary artery disease	5.08e-06	4.16e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HBA1—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3C2A—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2C19—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CSF2—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF1—coronary artery disease	5.06e-06	4.14e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOC3—coronary artery disease	5.03e-06	4.12e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	5.03e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—coronary artery disease	5.03e-06	4.11e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—coronary artery disease	5.02e-06	4.11e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LDLR—coronary artery disease	5e-06	4.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G1B—coronary artery disease	4.98e-06	4.08e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RPS6KB1—coronary artery disease	4.97e-06	4.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEF2C—coronary artery disease	4.97e-06	4.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCE—coronary artery disease	4.96e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—JAK2—coronary artery disease	4.96e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS1—coronary artery disease	4.95e-06	4.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GSK3B—coronary artery disease	4.95e-06	4.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—coronary artery disease	4.94e-06	4.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC9A1—coronary artery disease	4.94e-06	4.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—coronary artery disease	4.94e-06	4.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	4.93e-06	4.03e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—coronary artery disease	4.91e-06	4.02e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREB1—coronary artery disease	4.91e-06	4.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS3—coronary artery disease	4.89e-06	4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCLC—coronary artery disease	4.89e-06	4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CETP—coronary artery disease	4.89e-06	4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	4.87e-06	3.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ITGB3—coronary artery disease	4.85e-06	3.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KITLG—coronary artery disease	4.83e-06	3.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFBR2—coronary artery disease	4.83e-06	3.95e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDC1—coronary artery disease	4.83e-06	3.95e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—coronary artery disease	4.8e-06	3.93e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6R—coronary artery disease	4.79e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—coronary artery disease	4.73e-06	3.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT5A—coronary artery disease	4.72e-06	3.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP3—coronary artery disease	4.72e-06	3.87e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—coronary artery disease	4.72e-06	3.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP2CA—coronary artery disease	4.71e-06	3.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—coronary artery disease	4.7e-06	3.85e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—VCAN—coronary artery disease	4.7e-06	3.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOA—coronary artery disease	4.66e-06	3.81e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCD—coronary artery disease	4.62e-06	3.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOB—coronary artery disease	4.56e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMA6—coronary artery disease	4.56e-06	3.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMB5—coronary artery disease	4.56e-06	3.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—coronary artery disease	4.53e-06	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—coronary artery disease	4.53e-06	3.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DCN—coronary artery disease	4.53e-06	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C3—coronary artery disease	4.52e-06	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—JAK2—coronary artery disease	4.5e-06	3.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—coronary artery disease	4.49e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—coronary artery disease	4.49e-06	3.67e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—coronary artery disease	4.48e-06	3.67e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CTGF—coronary artery disease	4.46e-06	3.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—coronary artery disease	4.46e-06	3.65e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMGCR—coronary artery disease	4.42e-06	3.62e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT2—coronary artery disease	4.42e-06	3.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH2—coronary artery disease	4.4e-06	3.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF1—coronary artery disease	4.39e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—coronary artery disease	4.39e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—coronary artery disease	4.36e-06	3.57e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—coronary artery disease	4.34e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RPS6KB1—coronary artery disease	4.32e-06	3.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEF2C—coronary artery disease	4.32e-06	3.54e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—coronary artery disease	4.31e-06	3.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HBA1—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2C19—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3C2A—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—coronary artery disease	4.29e-06	3.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—coronary artery disease	4.28e-06	3.5e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOC3—coronary artery disease	4.26e-06	3.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LDLR—coronary artery disease	4.24e-06	3.47e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	4.23e-06	3.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITGB3—coronary artery disease	4.21e-06	3.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—coronary artery disease	4.21e-06	3.44e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—coronary artery disease	4.21e-06	3.44e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC9A1—coronary artery disease	4.19e-06	3.43e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—coronary artery disease	4.19e-06	3.43e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JAK2—coronary artery disease	4.16e-06	3.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—coronary artery disease	4.16e-06	3.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CETP—coronary artery disease	4.14e-06	3.39e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCLC—coronary artery disease	4.14e-06	3.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—coronary artery disease	4.12e-06	3.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—coronary artery disease	4.11e-06	3.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK14—coronary artery disease	4.09e-06	3.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDC1—coronary artery disease	4.09e-06	3.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP2CA—coronary artery disease	4.09e-06	3.35e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—coronary artery disease	4.08e-06	3.34e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLCB1—coronary artery disease	4.06e-06	3.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—coronary artery disease	4.02e-06	3.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCD—coronary artery disease	4.02e-06	3.29e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—coronary artery disease	3.97e-06	3.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—coronary artery disease	3.97e-06	3.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6ST—coronary artery disease	3.95e-06	3.23e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCA1—coronary artery disease	3.94e-06	3.22e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C3—coronary artery disease	3.92e-06	3.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—coronary artery disease	3.92e-06	3.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMB5—coronary artery disease	3.87e-06	3.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMA6—coronary artery disease	3.87e-06	3.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	3.86e-06	3.16e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—coronary artery disease	3.81e-06	3.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT1—coronary artery disease	3.81e-06	3.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—coronary artery disease	3.8e-06	3.11e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—coronary artery disease	3.8e-06	3.11e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CTGF—coronary artery disease	3.78e-06	3.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMGCR—coronary artery disease	3.74e-06	3.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT2—coronary artery disease	3.74e-06	3.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—coronary artery disease	3.74e-06	3.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—coronary artery disease	3.73e-06	3.05e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—coronary artery disease	3.67e-06	3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—coronary artery disease	3.65e-06	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—coronary artery disease	3.65e-06	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3B—coronary artery disease	3.64e-06	2.98e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—coronary artery disease	3.63e-06	2.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—coronary artery disease	3.61e-06	2.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREB1—coronary artery disease	3.61e-06	2.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—coronary artery disease	3.61e-06	2.96e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—coronary artery disease	3.61e-06	2.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—coronary artery disease	3.58e-06	2.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK14—coronary artery disease	3.56e-06	2.91e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—coronary artery disease	3.54e-06	2.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—coronary artery disease	3.54e-06	2.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6R—coronary artery disease	3.53e-06	2.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—coronary artery disease	3.49e-06	2.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—coronary artery disease	3.48e-06	2.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—coronary artery disease	3.46e-06	2.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—coronary artery disease	3.45e-06	2.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—coronary artery disease	3.45e-06	2.82e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLCB1—coronary artery disease	3.44e-06	2.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—coronary artery disease	3.43e-06	2.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6ST—coronary artery disease	3.43e-06	2.81e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—coronary artery disease	3.43e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—coronary artery disease	3.4e-06	2.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	3.39e-06	2.78e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—coronary artery disease	3.38e-06	2.77e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	3.38e-06	2.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCA1—coronary artery disease	3.34e-06	2.73e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—coronary artery disease	3.33e-06	2.73e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—coronary artery disease	3.33e-06	2.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—coronary artery disease	3.31e-06	2.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—coronary artery disease	3.3e-06	2.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—coronary artery disease	3.3e-06	2.7e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOB—coronary artery disease	3.24e-06	2.65e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT1—coronary artery disease	3.23e-06	2.64e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—coronary artery disease	3.23e-06	2.64e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—coronary artery disease	3.2e-06	2.62e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3B—coronary artery disease	3.16e-06	2.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—coronary artery disease	3.15e-06	2.58e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—coronary artery disease	3.15e-06	2.58e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—coronary artery disease	3.14e-06	2.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREB1—coronary artery disease	3.14e-06	2.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—coronary artery disease	3.09e-06	2.53e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—coronary artery disease	3.08e-06	2.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—coronary artery disease	3.07e-06	2.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAK2—coronary artery disease	3.06e-06	2.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6R—coronary artery disease	3.06e-06	2.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—coronary artery disease	3.02e-06	2.47e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—coronary artery disease	3.02e-06	2.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—coronary artery disease	3e-06	2.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—coronary artery disease	3e-06	2.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—coronary artery disease	2.94e-06	2.4e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—coronary artery disease	2.9e-06	2.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP2CA—coronary artery disease	2.9e-06	2.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	2.88e-06	2.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.87e-06	2.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—coronary artery disease	2.87e-06	2.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—coronary artery disease	2.86e-06	2.34e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—coronary artery disease	2.83e-06	2.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—coronary artery disease	2.82e-06	2.31e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—coronary artery disease	2.8e-06	2.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—coronary artery disease	2.78e-06	2.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—coronary artery disease	2.78e-06	2.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—coronary artery disease	2.78e-06	2.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOB—coronary artery disease	2.74e-06	2.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—coronary artery disease	2.74e-06	2.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—coronary artery disease	2.7e-06	2.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—coronary artery disease	2.68e-06	2.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—coronary artery disease	2.67e-06	2.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAK2—coronary artery disease	2.66e-06	2.18e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—coronary artery disease	2.66e-06	2.18e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—coronary artery disease	2.64e-06	2.16e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—coronary artery disease	2.62e-06	2.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—coronary artery disease	2.61e-06	2.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—coronary artery disease	2.6e-06	2.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—coronary artery disease	2.59e-06	2.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—coronary artery disease	2.56e-06	2.1e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—coronary artery disease	2.55e-06	2.09e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—coronary artery disease	2.53e-06	2.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—coronary artery disease	2.49e-06	2.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP2CA—coronary artery disease	2.46e-06	2.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—coronary artery disease	2.45e-06	2.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—coronary artery disease	2.43e-06	1.99e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—coronary artery disease	2.41e-06	1.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—coronary artery disease	2.36e-06	1.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—coronary artery disease	2.35e-06	1.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—coronary artery disease	2.32e-06	1.9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—coronary artery disease	2.31e-06	1.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—coronary artery disease	2.27e-06	1.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—coronary artery disease	2.26e-06	1.85e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—coronary artery disease	2.26e-06	1.85e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—coronary artery disease	2.24e-06	1.83e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—coronary artery disease	2.23e-06	1.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—coronary artery disease	2.2e-06	1.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—coronary artery disease	2.19e-06	1.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—coronary artery disease	2.17e-06	1.78e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—coronary artery disease	2.13e-06	1.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—coronary artery disease	2.13e-06	1.74e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—coronary artery disease	2.08e-06	1.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.08e-06	1.7e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—coronary artery disease	2.04e-06	1.67e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—coronary artery disease	2.03e-06	1.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—coronary artery disease	1.97e-06	1.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—coronary artery disease	1.97e-06	1.61e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—coronary artery disease	1.94e-06	1.59e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—coronary artery disease	1.91e-06	1.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—coronary artery disease	1.89e-06	1.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—coronary artery disease	1.81e-06	1.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—coronary artery disease	1.78e-06	1.45e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—coronary artery disease	1.77e-06	1.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—coronary artery disease	1.77e-06	1.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—coronary artery disease	1.72e-06	1.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—coronary artery disease	1.64e-06	1.35e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—coronary artery disease	1.57e-06	1.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—coronary artery disease	1.54e-06	1.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—coronary artery disease	1.5e-06	1.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—coronary artery disease	1.45e-06	1.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—coronary artery disease	1.36e-06	1.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—coronary artery disease	1.26e-06	1.03e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.09e-06	8.94e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—coronary artery disease	9.25e-07	7.57e-06	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—coronary artery disease	8.92e-07	7.3e-06	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—coronary artery disease	7.56e-07	6.18e-06	CbGpPWpGaD
